RxDoctor Payments Data

Robert Hart, MD

Urology · Fairfax, VANPI 1427030832

Payments from drug & device makers

$788in general payments, 2019–2025

Across 13 payments — averaging $60.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$224
  • Bioprotect Medical, Inc.$151
  • Procept Biorobotics Corporation$146
  • Astellas Pharma US Inc$100
  • AstraZeneca$75
  • Tolmar Pharmaceuticals, Inc.$60
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$68887%
  • Education$10013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 25th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$247,241
Medicare patients
815
Services billed
7,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron48$58,169
GemtesaVibegron19$23,016
Testosterone40$13,399
Tamsulosin Hcl588$11,878
Dutasteride200$8,016
Finasteride241$3,850
Oxybutynin Chloride ErOxybutynin Chloride112$3,294
Alfuzosin Hcl ErAlfuzosin Hcl110$2,559
Methenamine Hippurate12$920
Fesoterodine Fumarate ErFesoterodine Fumarate12$811
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$679
Bicalutamide13$645
CefuroximeCefuroxime Axetil29$454
Tadalafil15$432
Doxazosin Mesylate15$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$58,16948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 300 urology providers in Virginia.

Other urology in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →